AUROBINDO

October 7, 2019

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sirs,

Sub.: Reply to Clarification/Confirmation on news item appearing in www.thehindubusinessline.com"
Ref : Your e-mail dated October 7, 2019 Vide no. L/SURV/ONL/RV/SS/ (2019-2020)/ 112

This has reference to your aforesaid E-mail dated October 7, 2019, seeking clarification on news item appearing in www.thehindubusinessline.com. In this regard, we provide the following clarification:

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at our Unit 7 manufacturing facility from September 19-27, 2019.

The inspection ended with 7 observations. We believe none of the observations are related to data integrity. The Company is confident of addressing these issues within the stipulated timeline.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B Adi Reddy
Company Secretary

AUROBINDO PHARMA * HYD